{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T04:26:25Z","timestamp":1758860785457,"version":"3.44.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.kint.2018.02.019","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T08:57:06Z","timestamp":1525510626000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective"],"prefix":"10.1016","volume":"94","author":[{"given":"Laurent","family":"Alric","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Ollivier-Hourmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"B\u00e9rard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Hillaire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maeva","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anais","family":"Vallet-Pichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bernard-Chabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bourli\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"de Ledinghen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fouchard-Hubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Canva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Nguyen-Khac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Trias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2018.02.019_bib1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2010.09.023","article-title":"HCV infection and the incidence of CKD","volume":"57","author":"Butt","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.02.019_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2018.02.019_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/liv.13367","article-title":"Epidemiology update for hepatitis C virus and hepatitis B virus in end-stage renal disease in France","volume":"37","author":"Isnard Bagnis","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2018.02.019_bib4","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1681\/ASN.2016010030","article-title":"Hepatitis C virus infection in chronic kidney disease","volume":"27","author":"Ladino","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.02.019_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.kint.2018.02.019_bib6","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","article-title":"Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies","volume":"5","author":"Fabrizi","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2018.02.019_bib7","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1053\/gast.2002.36610","article-title":"Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection","volume":"123","author":"Alric","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2018.02.019_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"11","author":"Morales","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2018.02.019_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2018.02.019_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-014-0142-5","article-title":"Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations","volume":"53","author":"Kanter","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.kint.2018.02.019_bib11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.kint.2016.01.011","article-title":"New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant","volume":"89","author":"Fabrizi","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2018.02.019_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","article-title":"Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis","volume":"37","author":"Li","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2018.02.019_bib13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.02.019_bib14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2017.01.050","article-title":"Safety and efficacy of elbasvir\/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis","volume":"152","author":"Jacobson","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2018.02.019_bib15","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the\u00a0C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2018.02.019_bib16","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1086\/517339","article-title":"High rate of hepatitis C virus clearance in hemodialysis patients after interferon-\u03b1 therapy","volume":"176","author":"Izopet","year":"1997","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.kint.2018.02.019_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1053\/j.ajkd.2003.11.020","article-title":"Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN","volume":"43","author":"Alric","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2018.02.019_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1053\/j.gastro.2017.03.006","article-title":"Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis","volume":"153","author":"Saadoun","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2018.02.019_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","article-title":"Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs national health care system","volume":"151","author":"Loannou","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2018.02.019_bib20","first-page":"1615","article-title":"Effect of sofosbuvir-based hepatitis C\u00a0virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2018.02.019_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/liv.13078","article-title":"Sofosbuvir-based treatment is\u00a0safe and effective in patients with chronic hepatitis C infection and\u00a0end stage renal disease: a case series","volume":"36","author":"Singh","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2018.02.019_bib22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2018.02.019_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfw348","article-title":"Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure","author":"Dumortier","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2018.02.019_bib24","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourliere","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.02.019_bib25","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2018.02.019_bib26","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2018.02.019_bib27","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"17","author":"Levitsky","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2018.02.019_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.kint.2017.09.002","article-title":"Expanding the use of hepatitis\u00a0C-viremic kidney donors","volume":"92","author":"Sawinski","year":"2017","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818302096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253818302096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:49:43Z","timestamp":1758761383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253818302096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0085253818302096"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2018.02.019","relation":{},"ISSN":["0085-2538"],"issn-type":[{"type":"print","value":"0085-2538"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4\/5 severe chronic kidney disease is safe and effective","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2018.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}